Showing results (421-430 of 452) with videos related to
Sort By:
Pageof 46
Transplantation and Cellular Therapy|September 7, 2024
Transplant Outcomes in Myelofibrosis: Impact of Donor Type (Cord Blood Grafts Supported by CD34+ selected Cells [Haplo-Cord] Versus Matched Donors)Nima Ghalehsari, Franco Castillo Tokumori, Zhengming Chen, et al.Haematologica|October 15, 2020
Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemiaMark B Geyer, Ellen K Ritchie, Arati V Rao, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 15, 2015
Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study designCaroline A Lee, Meeghan A O'Connor, Tasha K Ritchie, et al.Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|September 16, 2015
Clinical and molecular epidemiology of human rhinovirus infections in patients with hematologic malignancySamantha E Jacobs, Daryl M Lamson, Rosemary Soave, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2015
Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617FBrady L Stein, Stephen T Oh, Dmitriy Berenzon, et al.Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|October 8, 2019
Incremental Utility of Right Ventricular Dysfunction in Patients With Myeloproliferative Neoplasm-Associated Pulmonary HypertensionJiwon Kim, Spencer Krichevsky, Lola Xie, et al.Frontiers in Oncology|September 16, 2021
Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AMLAmanda Lopez, Sanjay Patel, Julia T Geyer, et al.Blood Advances|March 17, 2026
Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy in patients with myelofibrosisJohn O Mascarenhas, Laura Maria Fogliatto, Steven D Green, et al.The New England Journal of Medicine|February 21, 2024
Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia VeraMarina Kremyanskaya, Andrew T Kuykendall, Naveen Pemmaraju, et al.The Lancet. Haematology|June 25, 2021
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trialJeffrey E Lancet, Geoffrey L Uy, Laura F Newell, et al.Pageof 46